Memantine Hydrochloride Tablet
Product Images NDC 63629-2513

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 63629-2513). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 01)

Chemical structure of Memantine Hydrochloride showing a tricyclic amine structure with methyl groups and a hydrochloride component.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 02)

A line graph depicting mean change from baseline in ADCS-ADL scores over weeks of treatment (0, 4, 12, 28) for Memantine Hydrochloride (M.HCl) versus placebo. The vertical axis shows mean change with clinical improvement and decline marked. Two curves show decline over time, with the placebo group declining more sharply than the Memantine Hydrochloride group.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 03)

A cumulative percentage chart depicting patients' response to Memantine Hydrochloride (M.HCl) versus placebo. The x-axis shows ADCS-ADL change from baseline, and the y-axis represents the cumulative percentage of patients. The graph compares the two groups, with Memantine Hydrochloride showing a higher cumulative percentage across changes than placebo.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 04)

A line graph showing mean change from baseline in SIB score over 28 weeks of treatment comparing Memantine Hydrochloride (M.HCl) and placebo. The x-axis denotes weeks of treatment from 0 to 28, and the y-axis shows mean change with SEM. The graph includes lines for placebo and M.HCl with markers and error bars, indicating clinical improvement and decline thresholds.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 05)

A cumulative percentage of patients graph comparing effects of Memantine Hydrochloride (M. HCl) and placebo on SIB (Severe Impairment Battery) change from baseline. The x-axis shows SIB change from baseline, while the y-axis shows cumulative percentage of patients. Two lines represent the dataset: one with open circles for M. HCl and one with black squares for placebo.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 06)

A line graph depicting the mean change from baseline in ADCS-ADL score over 24 weeks of treatment. The x-axis represents weeks of treatment (0 to 24), and the y-axis shows mean change with error bars. Two groups are compared: Placebo/Donepezil (black squares) and Memantine Hydrochloride/Donepezil (open circles). The graph highlights clinical improvement and decline reference lines.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 07)

A line graph showing the cumulative percentage of patients on the y-axis plotted against ADCS-ADL change from baseline on the x-axis. Two curves compare Placebo/Donepezil and Memantine Hydrochloride (M. HCl)/Donepezil treatment groups, illustrating patient response over a range of functional change values.*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 08)

A line graph depicting the mean change from baseline in SIB (Severe Impairment Battery) score over 24 weeks of treatment. Two treatment groups are shown: Placebo/Donepezil and Memantine Hydrochloride (M.HCl)/Donepezil. The y-axis measures the mean change in SIB score, with positive values indicating clinical improvement and negative values indicating clinical decline. The x-axis represents weeks of treatment from 0 to 24. Data points include error bars representing SEM (standard error of the mean).*

FDA Label Image

Memantine Hydrochloride Tablets (5b56b880 7a88 4d48 8291 96f38c791808 09)

A line graph showing the cumulative percentage of patients on the y-axis versus SIB (Severe Impairment Battery) change from baseline on the x-axis. Two data series are presented: one for Placebo/Donepezil (black squares) and one for Memantine Hydrochloride/Donepezil (open circles). The graph compares patient response distributions between these two treatment groups.*

FDA Label Image

Label (Lbl636292513)

Memantine Hydrochloride Tablets USP 5 mg label from Bryant Ranch Prepack. The label shows the NDC 63629-2513-1 and indicates packaging of 500 tablets for prescription use only. Storage instructions recommend controlled room temperature 20° to 25°C and dispensing in a tight container. The label includes barcodes and the BRP Pharmaceuticals logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.